LYNZA 150 MG

Lynza 150mg Tablet is classified as a PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitor, which is a type of cancer medication that contains Olaparib as its active ingredient. It is utilized in the treatment of pancreatic and prostate cancer. This medication may be administered on its own or in conjunction with other anticancer therapies.

It is important to avoid taking olaparib if you have an allergy to the active ingredient or any other components of the medication. If you experience symptoms such as breathlessness, chest pain, rapid heartbeat, fever, cough, or wheezing, contact your doctor immediately. Your healthcare provider will perform blood tests prior to and monthly during the treatment, as this medication may lower the levels of red blood cells (RBC), white blood cells (WBC), and platelets. Before starting treatment, inform your healthcare provider if you have been diagnosed with any issues related to your lungs, liver, heart, or kidneys.

This medication is not recommended for use during pregnancy, as it may pose risks to the fetus and could lead to miscarriage. Therefore, women of childbearing age should take a pregnancy test before starting this medication. It is advisable to continue using birth control for at least six months after completing treatment. Additionally, breastfeeding is not recommended while undergoing treatment, as it is unclear whether Lynza 150mg Tablet 30’S can be passed into breast milk. Men should refrain from donating sperm for at least three months following the end of treatment. It is essential to inform your doctor about all medications you are currently taking, including prescription drugs, over-the-counter medications, vitamins, and supplements.